PL2041282T3 - Kwasy nukleinowe wiążące sdf-i - Google Patents

Kwasy nukleinowe wiążące sdf-i

Info

Publication number
PL2041282T3
PL2041282T3 PL07786160T PL07786160T PL2041282T3 PL 2041282 T3 PL2041282 T3 PL 2041282T3 PL 07786160 T PL07786160 T PL 07786160T PL 07786160 T PL07786160 T PL 07786160T PL 2041282 T3 PL2041282 T3 PL 2041282T3
Authority
PL
Poland
Prior art keywords
sdf
nucleic acids
binding nucleic
binding
acids
Prior art date
Application number
PL07786160T
Other languages
English (en)
Inventor
Werner Purschke
Florian Jarosch
Dirk Eulberg
Klaus Buchner
Christian Maasch
Nicole Dinse
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of PL2041282T3 publication Critical patent/PL2041282T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
PL07786160T 2006-07-18 2007-07-18 Kwasy nukleinowe wiążące sdf-i PL2041282T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06014957 2006-07-18
EP07786160.7A EP2041282B1 (en) 2006-07-18 2007-07-18 Sdf-i binding nucleic acids
PCT/EP2007/006387 WO2008009437A2 (en) 2006-07-18 2007-07-18 Sdf-i binding nucleic acids

Publications (1)

Publication Number Publication Date
PL2041282T3 true PL2041282T3 (pl) 2018-07-31

Family

ID=38947372

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07786160T PL2041282T3 (pl) 2006-07-18 2007-07-18 Kwasy nukleinowe wiążące sdf-i

Country Status (16)

Country Link
US (5) US8314223B2 (pl)
EP (1) EP2041282B1 (pl)
JP (1) JP5380287B2 (pl)
KR (2) KR101561652B1 (pl)
CN (2) CN103555725B (pl)
AR (1) AR061929A1 (pl)
AU (1) AU2007276435C1 (pl)
BR (1) BRPI0714844B8 (pl)
CA (1) CA2658267C (pl)
DK (1) DK2041282T3 (pl)
ES (1) ES2663404T3 (pl)
MX (1) MX2009000656A (pl)
PL (1) PL2041282T3 (pl)
PT (1) PT2041282T (pl)
RU (1) RU2590709C2 (pl)
WO (1) WO2008009437A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2041282B1 (en) 2006-07-18 2018-01-03 Noxxon Pharma AG Sdf-i binding nucleic acids
CN101796188B (zh) * 2007-08-06 2014-10-29 诺松制药股份公司 Sdf-1结合核酸及其用途
JP5463621B2 (ja) 2008-02-27 2014-04-09 ソニー株式会社 標的物質の定量方法
EP2304031A2 (en) * 2008-06-11 2011-04-06 Bionucleon S.r.l. Inhibition of hrp-3 using modified oligonucleotides
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素(hepcidin)結合之核酸類
WO2012025251A1 (en) * 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
CN103108641B (zh) * 2010-09-09 2016-01-13 诺松制药股份公司 Sdf-1结合性核酸及其在癌症治疗中的用途
JP2014503187A (ja) * 2010-10-29 2014-02-13 ノクソン ファーマ エージー 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
JP2018505144A (ja) * 2014-12-17 2018-02-22 キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited 抗cxcl12抗体分子およびその使用
EP3443095A1 (en) * 2016-04-15 2019-02-20 Noxxon Pharma AG Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
US11221270B2 (en) * 2018-02-27 2022-01-11 Kevan M Evans Method and apparatus for detecting slow leaks
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
JP7327855B2 (ja) 2020-06-26 2023-08-16 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection
TW202430127A (zh) * 2023-01-19 2024-08-01 國立陽明交通大學 可用於遞送內質網壓力誘導劑或免疫療法的複合奈米粒及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
WO1992014843A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
WO1999048528A1 (en) * 1998-03-24 1999-09-30 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US6670149B1 (en) * 1999-03-01 2003-12-30 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel nucleic acids and uses therefor
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
DK1417488T3 (da) * 2001-06-07 2007-03-05 Chemocentryx Inc Cellemigrasionsassay
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
WO2006032143A1 (en) 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
EP1817414B1 (de) * 2004-11-29 2010-07-14 Noxxon Pharma AG Vasopressin bindende l-nukleinsäure
US7964191B2 (en) 2006-02-02 2011-06-21 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
EP2041282B1 (en) 2006-07-18 2018-01-03 Noxxon Pharma AG Sdf-i binding nucleic acids
ES2625798T3 (es) 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
US8114608B2 (en) 2006-11-30 2012-02-14 University Of Virginia Patent Foundation Methods for treating and diagnosing fibrotic and fibroproliferative diseases
CN101796188B (zh) 2007-08-06 2014-10-29 诺松制药股份公司 Sdf-1结合核酸及其用途
US20090274687A1 (en) 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders

Also Published As

Publication number Publication date
EP2041282A2 (en) 2009-04-01
BRPI0714844B1 (pt) 2019-10-01
AR061929A1 (es) 2008-10-01
AU2007276435B2 (en) 2013-01-24
MX2009000656A (es) 2009-03-25
US8314223B2 (en) 2012-11-20
WO2008009437A2 (en) 2008-01-24
CN101506364A (zh) 2009-08-12
CN101506364B (zh) 2013-10-30
US9035038B2 (en) 2015-05-19
US9822369B2 (en) 2017-11-21
BRPI0714844B8 (pt) 2023-04-18
EP2041282B1 (en) 2018-01-03
CA2658267A1 (en) 2008-01-24
DK2041282T3 (en) 2018-04-16
KR20090039717A (ko) 2009-04-22
US20210139909A1 (en) 2021-05-13
AU2007276435A1 (en) 2008-01-24
US20130041019A1 (en) 2013-02-14
JP5380287B2 (ja) 2014-01-08
HK1131184A1 (en) 2010-01-15
CA2658267C (en) 2021-03-30
ES2663404T3 (es) 2018-04-12
KR101466931B1 (ko) 2014-12-02
RU2009105494A (ru) 2010-08-27
US20150232853A1 (en) 2015-08-20
CN103555725A (zh) 2014-02-05
CN103555725B (zh) 2017-05-24
PT2041282T (pt) 2018-03-13
KR101561652B1 (ko) 2015-10-20
BRPI0714844A2 (pt) 2013-11-26
RU2590709C2 (ru) 2016-07-10
US20180163207A1 (en) 2018-06-14
JP2009543567A (ja) 2009-12-10
WO2008009437A3 (en) 2008-03-27
US20110112172A1 (en) 2011-05-12
KR20130090428A (ko) 2013-08-13
AU2007276435C1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
HRP20181833T1 (hr) Ekspresija proteina iz više nukleinskih kiselina
GB0706243D0 (en) Modified nucleic acids
IL186085A0 (en) Ghrelin binding nucleic acids
GB2449354B (en) Binding protein
IL176133A0 (en) Stapler
IL195066A0 (en) Cancer-related nucleic acids
EP1910534A4 (en) DNA-BINDING PROTEIN-POLYMERASE CHIMERAE
EP2077326A4 (en) NOVEL NUCLEIC ACID
GB0603160D0 (en) Nucleic acid
GB0611116D0 (en) Proteins
GB0612542D0 (en) Combinations comprising staurosporines
EP2050543A4 (en) CLAMP MACHINE
GB0601976D0 (en) Proteins
GB0620735D0 (en) Proteins
GB2453894B (en) Binding assembly
TWI371353B (en) Stapler
GB0520523D0 (en) Object binding
GB0605471D0 (en) Stapler
GB0605672D0 (en) Indirect heating
GB0612623D0 (en) Proteins
GB0612443D0 (en) Protein
GB0614682D0 (en) Proteins
GB0620304D0 (en) Protein
HU0600159D0 (en) Kvantitative pcr
GB2433914B (en) Book binding